{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007861","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.850508+00:00","generated_at":"2026-06-16T00:06:46.375846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phibro Q3 net income falls 43% to $10.0M; Animal Health sales up 11%","bullets":["Q3 net sales $245.7M (+3% YoY); net income $10.0M (-43%); diluted EPS $0.25 (-43%); adjusted diluted EPS $0.29 (-13%).","Animal Health segment net sales +11% to $164.4M; Mineral Nutrition -9% to $62.9M; Performance Products -17% to $18.3M.","Adjusted EBITDA $27.4M (-2% YoY); free cash flow -$43M trailing twelve months (inventory build of $43M).","Company reiterates FY2023 guidance: net sales $960M-$1B, adjusted diluted EPS $1.21-$1.31.","Management notes recessionary pressure in Mineral Nutrition; opened new autogenous vaccine facility in Brazil."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007861","json":"https://secwatch.observer/filing/0001558370-23-007861.json","markdown":"https://secwatch.observer/filing/0001558370-23-007861.md","text":"https://secwatch.observer/filing/0001558370-23-007861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/0001558370-23-007861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/pahc-20230503x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:06:46.375846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f59d0cf3294b0590df7b1c5fa2c0e7cc52601a2b","claim":"PHIBRO ANIMAL HEALTH CORP reported three months ended March 31, 2023 (compared to the three months ended March 31, 2022) results: revenue $245.7 million, net income $10.0 million, EPS diluted EPS of $0.25.","evidence_excerpt":"third quarter and year-to-date ended March 31, 2023. ​ Highlights for the three months ended March 31, 2023 (compared to the three months ended March 31, 2022) ​ - Net sales of $245.7 million, an increase of $6.1 million, or 3% - Net income of $10.0 million, a decrease of $7.6 million, or 43% - Diluted EPS of $0.25, a decrease of $0.19, or 43% - Adjusted EBITDA of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/0001558370-23-007861-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023 (compared to the three months ended March 31, 2022)"},{"label":"Revenue","value":"$245.7 million"},{"label":"Net income","value":"$10.0 million"},{"label":"EPS","value":"diluted EPS of $0.25"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}